Evaluation of immune checkpoint inhibitor efficacy for solid tumors with <i>CD274</i> (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database.

In contrast, with regard to TTNT and response rate, we detected a positive trend in the CD274 -amplified group.

also in 6,846 other papers

The number of patients with CD274 amplification evaluated in the present study is the largest to date, and a favorable trend for TTNT and response rate in patients treated with ICIs was observed for the CD274 -amplified group compared with the matched CD274 -non-amplified group.

also in 1,005 other papers